Avid Bioservices Seeks to Stand Out in The Pharmaceutical Industry

Photo of author
Written By Marcus Reynolds

The pharmaceutical services sector has emerged as a lucrative arena within the private markets, boasting over 80% private ownership.

However, amidst interesting industry dynamics, including Catalent’s monumental sale and the rising trend of pharma companies outsourcing manufacturing, a distinctive opportunity has emerged in the public markets—Avid Bioservices, Inc. (NASDAQ: CDMO).

Let’s delve into what sets Avid apart and why it could be a compelling long-term investment.

From Legacy to Innovation

Since its inception in 1993, Avid has been a stalwart in biologics manufacturing. However, its narrative took an exciting turn in 2018 when it pivoted to become a pure-play Contract Development and Manufacturing Organization (CDMO).

Credits: DepositPhotos

This strategic shift marked a paradigmatic change, with Avid embracing a service-centric approach, bolstering its sales force, and assembling a management team with deep manufacturing expertise.

Financial Outlook and Market Position

Management’s steadfast guidance reaffirms Avid’s robust market position, with FY24 revenue projected between $137-147 million. Notably, diversified bookings from major clients, particularly in later-stage programs, promise a bright future.

Moreover, operational expansions, including a new cell and gene therapy facility, enhance Avid’s revenue-generating capacity to approximately $400 million, positioning it for substantial growth.

Unveiling Avid’s Potential

Avid’s business model boasts several key strengths, offering investors an enticing proposition. Firstly, its mission-critical role in drug development endows it with an economic moat, characterized by long-term stability and predictable cash flows.

Furthermore, high barriers to entry and exit fortify its market position, underpinned by its strategic shift to a pure-play CDMO.

Tailwinds and Growth Opportunities

The winds of opportunity favor Avid, driven by strategic initiatives and market dynamics. Its specialization in biologics, the fastest-growing segment of drug development, positions it for sustained growth.

With scalable operations and expanding revenue capacity, Avid is poised to capitalize on rising demand for specialized manufacturing capabilities.

Potential Catalysts for Growth

Several catalysts loom on the horizon, promising to propel Avid’s trajectory. The recent acquisition of Catalent by Novo Holdings underscores market opportunities, potentially enhancing Avid’s market share.

Legislative initiatives such as the BIOSECURE Act and improving funding conditions further bolster Avid’s growth prospects. Additionally, the commercialization of former assets and private equity interest present avenues for value creation.

Market Dynamics and Competitive Landscape

While Avid’s specialization in manufacturing presents a competitive edge, the emergence of new players and potential insourcing by big pharma pose risks.

Credits: DepositPhotos

Operational challenges, including scale-up hurdles and regulatory compliance, could impact Avid’s performance and reputation. Moreover, dependency on the biologics market exposes it to industry-specific fluctuations.

Setting Sail with Avid Bioservices

Avid Bioservices emerges as a beacon of opportunity within the pharma services sector, offering investors a compelling proposition. Despite short-term volatility, Avid’s unique positioning as a pure-play CDMO and its strategic initiatives underscore its long-term potential.

With a conservative valuation suggesting substantial upside, coupled with promising catalysts on the horizon, Avid presents a captivating investment opportunity.

Avid Bioservices could have a lot of potential upside, and the company looks set to continue its recent rally.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.